Nisha Rajagopal,Graeme Hodgson,Emmanuelle Di Tomaso,Liv Helena Johannessen,Shanhu Hu
申请号：
US16621318
公开号：
US20200113902A1
申请日:
2018.06.12
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention relates to methods of identifying subjects suffering from various types of cancer who are more likely to respond to treatment with a covalent CDK7 inhibitor, such as N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-1-methylcyclohexyl)-5-((E)-4-(dimethylamino)but-2-enamido)picolinamide (Compound 1), either alone or in combination with other classes of anti-cancer therapies based on the presence or absence of certain biomarkers. In addition, the present invention relates to combinations of Compound 1 and one or more other anti-cancer therapies, kits containing them, and the use of such combinations in treating subjects suffering from various types of cancers.
